DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced that it has been awarded a $21 million National Institutes of Health contract to develop novel HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient’s immune system to recognize, target, and destroy unique features of their disease.
